News
VNDA
5.26
+0.77%
0.04
Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.0%, Outperforms Peers
Dow Jones · 12h ago
Weekly Report: what happened at VNDA last week (0810-0814)?
Weekly Report · 23h ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers
Dow Jones · 08/10 20:32
Vanda Pharmaceuticals Price Target Cut to $12.00/Share From $17.00 by B. Riley Securities
Dow Jones · 08/10 17:28
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12
Benzinga · 08/10 17:17
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)
TipRanks · 08/10 12:40
Vanda Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/10 10:32
Vanda Pharmaceuticals Price Target Cut to $20.00/Share From $21.00 by HC Wainwright & Co.
Dow Jones · 08/10 10:32
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
TipRanks · 08/10 10:10
Weekly Report: what happened at VNDA last week (0803-0807)?
Weekly Report · 08/10 09:13
Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.4%, Outperforms Peers
Dow Jones · 08/07 20:35
Vanda (VNDA) Gets a Buy from Cantor Fitzgerald
TipRanks · 08/07 18:25
Vanda Pharmaceuticals Balances Strong Growth With Rising Losses
TipRanks · 08/06 00:10
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/05 21:10
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
TipRanks · 08/05 20:05
*Vanda Pharmaceuticals 2Q Loss/Shr $1.04 >VNDA
Dow Jones · 08/05 20:01
*Vanda Pharmaceuticals 2Q Rev $50.5M >VNDA
Dow Jones · 08/05 20:01
Press Release: Vanda Pharmaceuticals Reports -3-
Dow Jones · 08/05 20:01
Vanda Pharmaceuticals Q2 Earnings Preview
Seeking Alpha · 08/04 21:35
Vanda Pharmaceuticals: The Tradipitant Timeline Matters More Than the Fanapt Numbers
Barchart · 08/04 16:37
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.